Juno Therapeutics (JUNO) Misses Q2 EPS by 4c

Juno Therapeutics (NASDAQ: JUNO) reported Q2 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $2.03 million.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c